THERAPEUTIC MODALITIES Archives - Page 8 of 22

Discovery Platform for Targeted Protein Degradation

In the last decade, targeted protein degradation (TPD) technology has become one of the most promising methods to remove specific...

OncoWuXi Express: Efficacy of DLL3 CAR-T in SHP-77 Tumor Models

OncoWuXi Express: Evaluation of DLL3 CAR-T in SHP-77-Luc Tumor Models Introduction: OncoWuXi Express will continue to keep you informed about...

Creating a Biological Switch Using DEL Technology

In addition to identifying chemical starting points for early drug discovery processes, DNA-encoded library (DEL) technology has now expanded to...

Recent Insights into Immuno-Oncology

The efficacy of CAR-T therapy is substantially influenced by the tumor microenvironment. This is particularly evident when PD-L1 is activated...

Integrated Platform of siRNA Drug Discovery

RNA interference using small interfering RNA (siRNA) molecules has emerged as a promising therapeutic modality. To accelerate the discovery of...

Integrated Screening in Hit Identification

Despite the availability of modern screening technologies, identification and optimization of hits against poorly druggable targets remains a significant challenge...

Oligonucleotide Discovery Services

Choose excellence, choose WuXi Biology- your reliable partner in oligonucleotide drug discovery. WuXi Biology provides an integrated service platform for...

Targeted Protein Degradation of Mutant ER-alpha

Estrogen receptor α (ERα) is considered the main driver in more than 70% of all breast cancers, making this transcription...

siRNA Efficacy in a Xenograft Tumor Model

Protein kinase N3 (PKN3) is a serine/threonine kinase implicated in tumor progression across multiple cancer types. PKN3 mRNA is almost undetectable in normal adult...

Knowledge Library